youtube_live
Q1 2027 earnings • released • EPS miss -41,60% • Revenue miss -0,51%
See resultschevron_right
DRREDDY:NSE
Dr Reddy's Laboratories Ltd
₹1 169,80
arrow_downward
-1,10%(-13,00) 1D
23 Jul., 15:30:00 GMT+5:30 · INR
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for DRREDDY...
Open
₹1 101,00
High
₹1 171,60
Low
₹1 101,00
Mkt. cap
970,10 mjd
Avg. vol.
2,28 m
Volume
6,69 m
Dividend
0,68%
Quarterly dividend
₹2,00
Ex-dividend date
10 Jul. 2026
P/E ratio
23,23
52-wk high
₹1 414,90
52-wk low
₹1 101,00
EPS
₹50,35
Shares outstanding
166,06 m
No. of employees
28 k
Open
₹1 101,00
High
₹1 171,60
Low
₹1 101,00
Mkt. cap
970,10 mjd
Avg. vol.
2,28 m
Volume
6,69 m
Dividend
0,68%
Quarterly dividend
₹2,00
Ex-dividend date
10 Jul. 2026
P/E ratio
23,23
52-wk high
₹1 414,90
52-wk low
₹1 101,00
EPS
₹50,35
Shares outstanding
166,06 m
No. of employees
28 k
News stories
From sources across the web
GuruFocus
·
2 uur gelede
Dr Reddy's Laboratories Ltd (RDY) Shares Surge 3.7% -- What GF S
TipRanks
·
6 uur gelede
Dr. Reddy’s Shareholders Approve New Independent Director and Auditor Appointments at AGM
Yahoo Finance
·
10 uur gelede
Dr. Reddy's Q1 Earnings and Revenues Miss Estimates, Stock Down
Stock Titan
·
14 uur gelede
Dr. Reddy’s Laboratories (NYSE: RDY) links June 2026 earnings call audio
Profile
Dr. Reddy's Laboratories Ltd. is an Indian multinational pharmaceutical company based in Hyderabad, with U.S. headquarters in East Brunswick, New Jersey. The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited. Dr. Reddy's manufactures and markets a wide range of pharmaceuticals in India and overseas. The company produces over 190 medications, 60 active pharmaceutical ingredients for drug manufacture, diagnostic kits, critical care, and biotechnology.
Dr. Reddy's began as a supplier to Indian drug manufacturers, but it soon started exporting to less-regulated markets that had the advantage of not having to spend time and money on a manufacturing plant that would gain approval from a drug licensing body such as the U.S. Food and Drug Administration. By the early 1990s, the expanded scale and profitability from these unregulated markets enabled the company to begin focusing on getting approval from drug regulators for their formulations and bulk drug manufacturing plants – in more-developed economies. This allowed their movement into regulated markets such as the US and Europe.
By 2007, Dr. Wikipedia
About Dr Reddy's Laboratories Ltd
CEOErez Israeli
Employees27,5 k
Founded1984
HeadquartersHyderabad, Andhra Pradesh, Indië
SectorPharmaceutical industry
Websitedrreddys.com
AI content may include mistakes. Learn more